13 / 16
Page 43
allied
academies
Biol Med Case Rep 2017 | Volume 1 Issue 2
November 06-07, 2017 | New Orleans, USA
Nanomedicine & Healthcare
Global Meet on
T
here is an increasing interest in the application of gold
nanoparticles in cancer therapy; however, their toxicity
should be carefully assessed before its application in
clinical trials. The present work was conducted to evaluate
the possible toxicity of intravenous injection of 50nm gold
nanorods; this included their effect on hematology, liver and
kidney functions, histopathology and TEM for liver, spleen
and kidney. Sixteen baladi dogs were divided into three
groups; control (n=5); acute toxicity (n=5), and long term
acute toxicity (n=6) groups. Dogs in the treated groups were
intravenously injected with 75µg of 50nm AuNRs/kg body
weight, while dogs in the control group were injected with
normal saline solution. Blood samples were collected before
AuNRs injection, on day-15 and on day-30 after AuNRs
injection to study the acute, and up to the six months after
AuNRs injection to study the long term acute toxicity, and
from control group, blood samples were collected at the
same times. Biopsy samples were collected from the control
and after the first and six months of AuNRs injection and
prepared for histopathology and TEM examination.Blood
samples were analyzed for complete blood count, liver
and kidney functions. Results showed no aberrant clinical
changes after intravenous injection of AuNRs in dogs. Also,
no gross morphological changes in size, color and texture of
liver, kidney and spleen were detected at biopsy sampling.
Histopathological examinationof thebiopsy samples revealed
that, intravenous injection of AuNRs produced mild changes
in liver and kidney in at long term acute toxicity group, while
spleen tissues were not affected by AuNRs injection. TEM
failed to detect AuNRs in spleen, kidney or liver of treated
animals either in acute or long term acute toxicity groups.
There were mild changes in RBCs, HGB, MCM, total protein,
globulin, total bilirubin and creatinine levels in the blood
samples taken from dogs in both AuNRs groups compared
with control dogs. In conclusion, intravenous injections of
AuNS did not elicit harmful effect on liver, kidney or spleen
of dogs; therefore, it can be safely used in cancer therapy in
dogs without any impairment of their physiological functions.
e:
assabdoon@yahoo.comSafety of intravenous injection of 50nm gold nanorods (AuNRS) in dogs
Ahmed S S Abdoon
1
, Khaled M Hussein
2
, Aminah A Gamal El Din
1
, Omaima M Kandil
1
, Emad A Al Ashkar
1
, Ahmed M Shaban
1
, Soad M Nasr
1
, Badawi A
Anis
1
, Ashraf H Shaalan
1
and
Mostafa A El-Sayed
3
1
NRC, Egypt
2
Cairo University, Rgypt
3
Georgia Institute of Technology, USA